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Abstract: Although the causes of hepatotoxicity among alcohol-abusing HIV patients are multifactorial, alcohol remains the least explored “second hit” for HIV-related hepatotoxicity. Here, we
investigated whether metabolically derived acetaldehyde impairs lysosomes to enhance HIV-induced
hepatotoxicity. We exposed Cytochrome P450 2E1 (CYP2E1)-expressing Huh 7.5 (also known as
RLW) cells to an acetaldehyde-generating system (AGS) for 24 h. We then infected (or not) the cells
with HIV-1ADA then exposed them again to AGS for another 48 h. Lysosome damage was assessed
by galectin 3/LAMP1 co-localization and cathepsin leakage. Expression of lysosome biogenesis–
transcription factor, TFEB, was measured by its protein levels and by in situ immunofluorescence.
Exposure of cells to both AGS + HIV caused the greatest amount of lysosome leakage and its impaired
lysosomal biogenesis, leading to intrinsic apoptosis. Furthermore, the movement of TFEB from cytosol to the nucleus via microtubules was impaired by AGS exposure. The latter impairment appeared
to occur by acetylation of α-tubulin. Moreover, ZKSCAN3, a repressor of lysosome gene activation by
TFEB, was amplified by AGS. Both these changes contributed to AGS-elicited disruption of lysosome
biogenesis. Our findings indicate that metabolically generated acetaldehyde damages lysosomes and
likely prevents their repair and restoration, thereby exacerbating HIV-induced hepatotoxicity.
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1. Introduction
Since the emergence of antiretroviral therapy, a significant decline in AIDS-related mortality among people living with HIV (PLWH) precipitated an upsurge in non-AIDS-related
mortality (NARM). Comorbidities implicated in NARM among PLWH are cardiometabolic
disorders, renal disease, mental illness, and liver disease [1]. While cardiometabolic disease
ranks as the leading comorbidity among PLWH [2], liver disease remains the leading
injury for NARM, accounting for approximately one-fifth of all cases [3–5]. This makes the
management of liver disease a priority for HIV care delivery. Pathogenesis of HIV-related
liver comorbidities is exacerbated by “second hits”, such as alcohol or co-infection with
hepatotropic viruses [6]. However, the mechanism(s) by which alcohol induces liver injury
during HIV infection is/are not entirely clear, which prevents improving a holistic treatment strategy. Thus, an understanding of the mechanisms of HIV- and alcohol-induced
hepatotoxicity is the goal of this study.
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We recently showed that in HIV-infected liver cells, ethanol and/or its metabolite
acetaldehyde cause accumulation of HIV proteins to induce oxidant stress and subsequent
apoptotic cell death [7]. This may lead to detrimental consequences and promote the
development of end-stage liver diseases since HIV-particle-bearing apoptotic hepatocytes
are engulfed by hepatic stellate cells (HSC) and macrophages (Mph), to induce profibrotic
and proinflammatory events, leading to the progression of liver fibrosis [7].
In untreated liver cells, lysosomes degrade HIV proteins, thereby preventing their
intracellular accumulation and subsequent oxidant stress [7,8]. While lysosome dysfunction by ethanol has been reported [9,10], it has not been implicated in the pathogenesis of
HIV/alcohol-induced liver injury. Here, we characterized the contribution of acetaldehyde,
the primary oxidation product of ethanol, and its ability to impair lysosome function in
HIV-exposed liver cells. First, we investigated whether the alcohol-induced decline in
cathepsin activities was accompanied by decreased lysosome numbers. Second, we determined whether acetaldehyde-induced lysosome leakage triggered the cathepsin decline.
Lysosome damage/rupture causes the release of cathepsins and other hydrolases into the
cytosol. While the etiology of lysosome damage and subsequent leakage are diverse, ROS
production induces such damage [11]. Here, we used an in vitro acetaldehyde-generating
system (AGS) that continuously generates physiologically relevant amounts of acetaldehyde and mimics ethanol metabolism in HIV-infected Huh 7.5 (also known as RLW) cells
that overexpress cytochrome P450 2E1 (CYP2E1), but not alcohol dehydrogenase (ADH).
AGS generates acetaldehyde by using ethanol as the primary substrate of yeast alcohol
dehydrogenase in the presence of nicotinamide adenine dinucleotide (NAD+ ) as a co-factor.
Exposure of cells to the AGS elevates ROS levels in RLW cells since ethanol is part of
AGS, and RLW cells generate ROS by CYP2E1 upon ethanol exposure [7]. Hence, we
postulated that in HIV-exposed RLW cells, the decrease in cathepsin activities is due to
lysosome leakage triggered by enzymatically generated acetaldehyde and oxidant stress,
which mimics ethanol metabolism in primary hepatocytes. Such leakage is detrimental if
lysosome repair/replacement is inhibited as well. The activity and intracellular localization
of Transcription Factor EB (TFEB), which activates genes that encode lysosomal proteins
and lysosome biogenesis [12], is disrupted by chronic ethanol administration [13,14]. Here,
we sought to determine whether HIV and AGS prevent TFEB translocation from cytosol
to the nucleus of HIV-infected RLW cells. TFEB nuclear translocation activates genes
involved in lysosome biogenesis. TFEB nuclear translocation/gene activation is prevented
by its phosphorylation [15], by reduced proteasomal degradation in the cytosol [16], and
by impaired TFEB trafficking; an increased expression of ZKSCAN3, a transcriptional
repressor of autophagy [17], also affects lysosomal gene activation. We hypothesized that
exposure of hepatocytes to HIV and ethanol and its metabolite, acetaldehyde, induces
oxidant stress to trigger lysosome leakage and lysosome biogenesis suppression. The latter
suppression blocks intracellular replacement of damaged lysosomes causing cytotoxicity
during combined HIV and alcohol/acetaldehyde exposure to liver cells.
2. Materials and Methods
2.1. Reagents and Antibodies
High-glucose Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum
were purchased from Invitrogen (Waltham, MA, USA); Trizol was from Life Technologies (Carlsbad, CA, USA); primer probes, high-capacity reverse transcription kit, and
real-time polymerase chain reaction (RT-PCR) reagents were from Applied Biosystems
by Thermo Fisher Scientific, Carlsbad, CA, USA. Pan-caspase inhibitor (PCI) was obtained from Ubiquitin-Proteasome Biotechnologies (UBPBio) Inc. (Cat#F7110, Aurora,
CO, USA), Nocodazole was from Sigma Aldrich (St. Louis, MO, USA, M1404). Primary
antibodies were: (a) mouse monoclonal: anti-TFEB (Santa Cruz Biotechnology, Dallas,
TX, USA, sc-166736), anti-cathepsin B (H-5) (sc-365558), anti-TATA binding protein (Millipore Sigma, Burlington, MA, USA, MAB3658), anti-beta-actin (Santa Cruz Biotechnology,
Dallas, TX, USA, sc-69879), anti-LAMP1 (Santa Cruz Biotechnology, Dallas, TX, USA,
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sc-20011), anti-Acetylated α-tubulin (Millipore Sigma, Burlington, MA, USA, T6793), antiα-tubulin (Millipore Sigma, Burlington, MA, USA, T9026); (b) rabbit monoclonal and
polyclonal anti-TFEB, 4240S; anti-Phospho-TFEB (ser211), 37681S; anti-Tom20 (D8T4N),
42406; anti-Galectin-3/LGALS3 (D4I2R), #87985; anti-ZKSCAN3 (LSBio, Seattle, WA, USA,
LS-C501696); (c) secondary antibodies: (I) IRDye 680RD Goat anti-Rabbit, C50317-02; IRDye
680RD Donkey anti-Mouse, C50520-02; (II) Goat anti-Mouse IgG (H + L) Cross-Adsorbed
Secondary Antibody, Alexa Fluor 555, Carlsbad, CA, USA, A21422; and Donkey anti-Rabbit
IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488.
2.2. In Vitro Studies
Due to the paucity of primary human hepatocytes, we performed all experiments on
hepatocyte-like RLW cells. These cells have reduced innate immunity and do not sufficiently oxidize (metabolize) ethanol because they lack ADH. To circumvent this limitation,
we exposed RLW cells to an exogenous constant source of acetaldehyde (acetaldehydegenerating system, AGS), which consists of 0.02 EU yeast alcohol dehydrogenase (ADH),
2 mM nicotinamide adenine dinucleotide (NAD), and 50 mM ethanol. AGS is known to
continuously generate a physiologically relevant amount of acetaldehyde without unwarranted toxicities [7]. HIV-1ADA propagated on primary human macrophages was purified
at University of Nebraska Medical Center (UNMC) [18]. RLW cells were pre-treated for
24 h with AGS, infected with HIV-1ADA , and then exposed again to AGS for another 48 h.
HIV was removed after overnight treatment, and the cells were washed thoroughly with
1× phosphate-buffered saline (PBS) to remove extracellular HIV.
2.3. RNA Isolation and Real-Time PCR (RT-PCR)
RNAs encoding p53, cathepsin D, and LAMP1 were quantified by RT-PCR as previously described [7]. Briefly, total cellular RNA was isolated from cells using Trizol reagent.
A two-step procedure was used, in which 200 ng RNA was reverse-transcribed to cDNA
using the high-capacity reverse transcription kit. In the second step, the cDNA was amplified using TaqMan Universal Master Mix II with fluorescent-labeled primers (TaqMan
gene expression systems). These were incubated in a Model 7500 qRT-PCR thermal cycler.
The relative quantity of each RNA transcript was calculated by its threshold cycle (Ct) after
subtracting that of the reference (GAPDH).
2.4. Proteasome Activities
Chymotrypsin (Cht-L) and trypsin-like (T-L) peptidase activities were detected by
in vitro fluorometric assay as previously reported by our laboratory [19]. Fluorogenic
peptide substrates N-succinyl-leu-leu-val-tyr-7-amido-4-methlycoumarin (suc-LLVY-AMC;
UBPBio, Inc., Aurora, CO, USA) and boc-leu-ser-thr-arg-7-amido-4-methlycoumarin
(boc-LSTR-AMC; UBPBio, Inc., Aurora, CO, USA) were used to measure chymotrypsinand trypsin-like activities of the proteasome.
2.5. Cathepsin B and L Activities
Cathepsin B and L activities were measured as previously described [20], using
Z-arg-arg-7-amido-4-methylcoumarin hydrochloride (cathepsin B) and L-phe-arg-7-amido4-methylcoumarin hydrochloride (cathepsin L).
2.6. Whole-Cell Lysates and Nuclear/Cytosolic Fractionations
Whole-cell lysates were prepared in phosphorylation capture buffer (0.5 M EDTA, 2 M
Tris, 20 mM Na3 VO4 , 200 mM Na4 P2 O7 , 100 mM PMSF, 1 M NaF, 20% Triton X-100, and
aprotinin, pH 7). The extraction of the nuclear and cytosolic components from RLW cells
was performed using the NE-PER Nuclear and Cytoplasmic Extraction Kit (ThermoFisher
Scientific, Carlsbad, CA, USA) based on the manufacturer’s protocol.
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2.7. Immunoblotting
Immunoblotting was performed as described [21,22]; blots were developed using
Odyssey infrared imaging system, which was also used to quantify the protein bands [23].
Equal (20 µg) amounts of protein were loaded in each lane. Beta-Actin or TATA-binding
proteins (TBP) were used as loading controls to normalize the protein band densities.
2.8. Immunofluorescence
RLW Cells (130,000/well) were seeded onto coverslips, which were inserted into each
well of a 12-well plate. Cells were infected with the HIV-1 virus (Multiplicity of infection,
MOI = 0.1). After overnight incubation of cells with HIV, the virus-containing medium was
removed and replenished with fresh media. Cells were incubated for another 48 h of AGS
treatment; cells were washed with 1× PBS, fixed with 4% paraformaldehyde for 12 min at
37 ◦ C, permeabilized with 0.1% Triton X-100 for 3 min at room temperature, and blocked
for 30 min with 1% (g/vol) bovine serum albumin (BSA) in PBS. Cells were stained to study
the colocalization of LAMP1:Galectin 3, Tom20:Cathepsin-B, and quantification of LAMP1.
First, cells were incubated with primary antibodies for 1 h. The cells were then washed
and incubated with the mixture of Alexa-Fluor-labeled secondary antibodies for 30 min.
Nuclei were stained with DAPI. The coverslips were transferred to microscope slides for
imaging by using LSM 710 confocal microscope. Immunostainings and colocalization were
quantified for intensity using National Institute of Health (NIH) Image J program.
2.9. Statistical Analyses
Data were analyzed using GraphPad Prism v7.03 software (GraphPad, La Jolla,
CA, USA). Data from at least three duplicate independent experiments were expressed as
mean ± SEM. Comparisons among multiple groups were performed by one-way ANOVA,
using a Tukey post hoc test. For comparisons between two groups, we used Student’s t-test.
A p-value of 0.05 or less was considered significant.
3. Results
3.1. AGS and HIV Exposure Lowers Cathepsin Activities and Lysosome Numbers
To understand the mechanism(s) by which HIV and acetaldehyde induce accumulation
of HIV proteins in hepatocytes, we measured cathepsin B and L activities as indices of
lysosomal enzyme function. The combination of AGS and HIV treatment (AGS + HIV)
decreased (p < 0.05) cathepsin B and L activities (Figure 1A,B). To determine whether lower
cathepsin B and L activities by AGS + HIV exposure reflected lower lysosome numbers,
we measured LAMP1 immunofluorescence intensity. Images were normalized to the
number of cells in each field. LAMP1 intensity was 42% lower in AGS-treated uninfected
cells, and this was further suppressed in HIV-infected cells (Figure 1C,D). Similarly, AGS
decreased LAMP1 protein expression of HIV-infected cells as demonstrated on Western
blots (Figure 1E,F). AGS exposure suppressed lysosome numbers in both HIV-infected and
-uninfected RLW cells, and AGS + HIV suppressed lysosome functions in RLW cells.
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Figure 1. Acetaldehyde Generating System (AGS) exposure lowered cathepsin activities and
lysosome numbers in HIV-infected and -uninfected RLW cells (RLW cells were treated as described in Materials and Methods). Specific activities of (A) Cathepsin B, and (B) Cathepsin L.
(C) Immunofluorescent staining of LAMP1. Staining was visualized using a 63× lens in LSM 710
confocal microscope. Pictures are representative data from three independent experiments. (D) Quantification of LAMP1-stained lysosomes. LAMP1 immunofluorescence intensity was measured using
ImageJ. (E,F) LAMP1 was measured by immunoblot analysis and quantification of immunoreactive
protein bands. Data are from 3 independent experiments presented as mean ± SEM. Bars marked
with the same letter are not significantly different; bars with different letters are significantly different
from each other (p ≤ 0.05).
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3.2. Both AGS and HIV Enhance Lysosome Leakage
We investigated whether AGS-induced LAMP1 suppression affected lysosome membrane permeabilization and lysosomal leakage (LL) in HIV-infected and -uninfected
cells. To this end, we quantified the levels of damage-regulatory autophagy modulator
(DRAM)-1, which induces lysosome leakage, thereby triggering p53-dependent apoptosis [24]. Since we found that AGS treatment increased p53 mRNA levels in both infected
and uninfected RLW cells (Figure 2A), we postulated that DRAM1 expressing cells would
be cleared by apoptosis. In fact, it was observed that AGS and AGS + HIV exposed cells
expressed a very low amount of DRAM1 (Figure 2B,C) because DRAM1-expressing cells
were unaccounted for due to apoptosis. To prevent/slow the clearance of DRAM-positive
cells, we measured DRAM expression after blocking apoptosis by a pan-caspase inhibitor
(PCI). In the presence of PCI, we observed 64% higher levels of intracellular DRAM in
AGS-exposed HIV-infected cells (Figure 2D,E). To further confirm these findings, we measured the co-localization of galectin 3 and LAMP1 puncta and found that AGS exposure
exhibited greater co-localization of galectin 3 and LAMP1 puncta in HIV-infected cells
than in uninfected cells (Figure 2F,G), indicating that both HIV and acetaldehyde exposure
contributes to lysosome leakage.

Figure 2. AGS and HIV enhance lysosomal leakage in RLW cells treated as indicated in Materials and Methods.
(A) p53 mRNA levels were measured by RT-PCR with GAPDH mRNA as the internal standard. (B,C) DRAM1 protein expression in the absence of pan-caspase inhibitor (PCI) was detected by immunoblotting. Quantification of protein
bands from 3 independent experiments is presented. Equal (20 µg) amounts of protein were loaded in each lane (as stated
in Materials and Methods). β-actin was used as the internal standard. (D,E) DRAM1 protein expression in the presence
of PCI was detected by immunoblotting. Quantification of protein bands from 3 independent experiments is presented.
(F) Co-localization of galectin 3 and LAMP1 was measured by immunofluorescence. Proteins were visualized using a
40× lens LSM 710 confocal microscope. (G) Co-localization of galectin 3 and LAMP1 was quantified using NIH Image J.
Data are from 3 independent experiments presented as mean ± SEM. Bars marked with the same letter are not significantly
different from each other; bars with different letters are significantly different from each other (p ≤ 0.05).
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3.3. AGS and HIV Enhance Intracellular Oxidant Stress
We investigated the contribution of oxidant stress to AGS-induced decline of cathepsin activities in control and HIV-exposed RLW cells as well as downstream apoptosis.
Combined AGS and HIV exposure suppressed cathepsin B and L activities and caused an
increase in apoptosis, detected by ELISA as elevated levels of M30 (cleaved cytokeratin 18)
in cell supernatants. M30 detection was significantly lower (p < 0.05) after treatment of cells
with N-acetyl cysteine (NAC), which restored cathepsin B and L activities (Figure 3A–C).

Figure 3. N-acetyl cysteine treatment prevents/reverses AGS and HIV-induced lysosomal leakage (RLW cells were treated
as indicated in Materials and Methods). (A,B) Cathepsin B and Cathepsin L activities were measured in cell lysates (in the
presence or absence of NAC) by fluorometric assay, using fluorimetric substrates. (C) Apoptosis was measured by M30
levels in cell culture supernatants. Data are from 3 independent experiments. Bars marked with the same letter are not
significantly different from each other; bars with different letters are significantly different from each other (p ≤ 0.05).

3.4. AGS and HIV Enhance Cathepsin Leakage and Intrinsic Apoptosis
We measured the leakage of cathepsin B from lysosomes and its translocation to the
outer mitochondrial membrane, which likely damages the mitochondrial membrane. In
AGS + HIV-treated cells, cathepsin B was co-localized with mitochondria, as indicated
by immunofluorescent co-localization of cathepsin B and Tom20. Tom20 is a protein on
the mitochondrial outer membrane that facilitates the import of mitochondrial precursor
proteins into the mitochondrion [25,26] (Figure 4A,B). Furthermore, caspase 3 cleavage in
AGS-exposed HIV-infected liver cells (the condition with the highest cathepsin B–Tom20
co-localization and apoptotic effects) was suppressed nearly three-fold in the presence
of 20 µM caspase 9 inhibitor, while the caspase 8 inhibitor had a minimal effect on the
observed apoptosis (Figure 4C,D).
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Figure 4. AGS and HIV enhance cathepsin B-triggered caspase 3-dependent apoptosis (RLW cells were treated as described
in Materials and Methods) (A,B) Immunofluorescence detection of co-localization of Cathepsin B and Tom20 and quantification of staining. Staining was visualized using a 40× lens in LSM 710 confocal microscope, and staining intensity
was quantified using NIH ImageJ. (C,D) Cleaved caspase-3 was measured by immunoblot analysis and quantification of
immunoreactive bands from 3 independent experiments. Data are from 3 independent experiments presented as mean
values ± SEM. Bars marked with the same letter are not significantly different from each other; bars with different letters
are significantly different from each other (p ≤ 0.05).

3.5. AGS and HIV Exposure Suppress TFEB Protein Expressions in Cytosolic and Nuclear
Fractions of RLW Cells
Lysosome damage reportedly activates lysosome biogenesis as a compensatory mechanism to replace damaged lysosomes [27] via enhanced TFEB transcription [15]. After
we separated nuclear and cytosolic fractions from the control and treated RLW cells, we
observed greater amounts of immunoreactive TFEB in the cytosolic fractions of HIV- and
AGS-treated cells. Both treatments significantly decreased the nuclear to cytosolic TFEB
ratios compared with untreated cells (Figure 5A,B).
The purities of our nuclear and cytosolic fractions were confirmed by Western blotting
by exposing both fractions to anti-α-tubulin (a cytosolic marker) and to the anti-TATA
binding protein (a nuclear marker) (Figure 5C).
Suppression by AGS of nuclear TFEB expression in HIV-infected and -uninfected cells
prompted us to analyze the role of ethanol metabolism on the factors that regulate TFEB
cytosolic-nuclear shuttling. As reported, mTORC1-mediated TFEB phosphorylation is an
upstream event, which causes TFEB retention in the cytosol [15]. Surprisingly, we observed the
downregulation of TFEB phosphorylation (pTFEB) at the mTOR-regulated serine sites (S211)
in both AGS-exposed uninfected and HIV-infected cells, which decreased the pTFEB/TFEB
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ratio (Figure 5D,E). To test whether microtubules regulate TFEB trafficking to the nucleus, RLW
cells were exposed for 24 h to 10 µM nocodazole, a microtubule-disrupting drug. We found
that TFEB nuclear translocation was attenuated by nocodazole, indicating that translocation
is microtubule-dependent (Figure 5F,G). We also found that exposure of HIV-infected and
-uninfected RLW cells to AGS enhanced α-tubulin acetylation (Figure 5H,I).

Figure 5. Suppression by AGS and HIV of transcription factor EB (TFEB) protein expression in cytosolic and nuclear
fractions of RLW cells. (A) nuclear and cytosolic TFEB protein expressions were measured by immunoblot analysis. Equal
(20 µg) amounts of protein were loaded in each lane. β-actin and TATA-binding proteins (TBP) were used as internal controls.
(B) Quantification of nuclear and cytosolic TFEB ratios from 3 independent experiments. (C) Immunoblot analysis to confirm
the purity of cytosolic and nuclear fractions. Equal amounts of cytosolic and nuclear proteins were loaded onto gels and
blotted onto nitrocellulose. α-tubulin was checked in nuclear fractions and TBP in cytosolic fractions. (D) Immunoblotting
analysis of phospho TFEB serine 211 protein expressions. Equal (20 µg) amounts of protein were loaded in each lane. β-actin
and total TFEB were used as an internal control. (E) Quantification of serine 211 phosphorylation/total TFEB ratios. Data
are from 3 independent experiments, presented as the mean ± SEM. Bars marked with the same letter are not significantly
different from each other; bars with different letters are significantly different (p ≤ 0.05). (F) Nuclear and cytosolic TFEB
was measured by immunoblotting analysis. Equal (20 µg) amounts of protein were loaded in each lane. β-actin and TBP
were used as an internal control (G) Quantification of nuclear to cytosolic TFEB ratios from 3 independent experiments.
(H,I) Acetylated tubulin was measured by immunoblot analysis and quantification of protein bands from 3 independent
experiments. Data are from 3 independent experiments presented as mean ± SEM. Bars marked with the same letter are not
significantly different from each other; bars with different letters are significantly different (p ≤ 0.05).

3.6. AGS and HIV Exposures Suppress Proteasome Activity and Enhance ZKSCAN3 Expression
Because TFEB is degraded by the proteasome, we examined whether HIV or AGS
influences 20S proteasome peptidase activities. HIV infection suppressed chymotrypsin
and trypsin-like activities (Figure 6A,B). However, this effect was exacerbated in AGS-exposed
HIV-infected and -uninfected RLW cells.
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We explored whether acetaldehyde influenced TFEB induced activation of lysosomal
genes. To this end, we measured the levels of ZKSCAN3 in RLW nuclear fractions as
ZKSCANS represses TFEB-activated lysosome biogenesis. We observed a 40% rise in
ZKSCAN3 expression after AGS treatment in both HIV-exposed and -unexposed RLW cells
(Figure 6C,D). To corroborate these findings, we quantified the mRNAs encoding LAMP1
and cathepsin D, two genes activated by TFEB. Both LAMP1 and cathepsin D mRNAs
were lower after cells were treated with AGS. This suppression effect was even greater in
AGS + HIV-infected cells (Figure 6E).

Figure 6. AGS and HIV enhance ZKSCAN3 but suppress TFEB target genes. (A,B) Cht-L, and T-L proteasome peptidase
activities were detected in cell lysates by in vitro assay using fluorimetric substrates (C) Immunoblot analysis of ZKSCAN3
protein expression in RLW nuclear fraction. Equal (20 µg) amounts of protein were loaded in each lane. β-actin was used as
an internal control. (D) Quantification of immunoreactive bands of ZKSCAN3 from 3 independent experiments. (E) LAMP1
and cathepsin D mRNA expression detected by RT-PCR analysis. GAPDH mRNA was used as an internal control. Data are
from 3 independent experiments, presented as the mean ± SEM. Bars marked with the same letter are not significantly
different from each other; bars with different letters are significantly different (p ≤ 0.05).

4. Discussion
As revealed from our previous studies, pre-exposure of hepatocytes to the ethanol
metabolite acetaldehyde sensitizes cells to HIV-induced apoptotic cell death. This was
partly due to acetaldehyde-induced intracellular accumulation of HIV proteins, which
occurs due to suppression of HIV protein degradation by both the proteasome and lysosomes [7]. In fact, inhibition of protein-degrading enzyme activities with specific inhibitors,
MG132 and carfilzomib for proteasomes or bafilomycin and chloroquine for lysosomes,
prolongs the persistence of HIV proteins in hepatocytes [7]. As reported by others, HIV
proteins are degraded by proteasomes and lysosomes [28–31]. We showed that the accumulation of HIV proteins in hepatocytes was greater after treatment with lysosome inhibitors
than with proteasome inhibitors. These findings underscore the importance of ethanol-
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and HIV-induced lysosomal dysfunction/damage for HIV protein retention, which can
cause oxidative stress. In kinetic studies, we indeed observed that the accumulation of
HIV proteins after exposure to AGS induces oxidative stress accompanied by ROS release,
which leads to apoptotic hepatocyte death [7]. The latter event results in the formation of
apoptotic bodies, which are engulfed by non-parenchymal (Kupffer) cells as we observed
in some canonical hepatotropic infections, such as HCV-infection, and were able to further
confirm in HIV infection [21,32].
Here, we addressed the contribution of lysosomal impairment to HIV alcohol-metaboliteinduced hepatotoxicity. Our results lead us to suggest that acetaldehyde induces lysosomal
damage in HIV-infected hepatocytes and that leakage of lysosomal luminal content (cathepsins) to other cell compartments may damage adjacent organelles, which hastens hepatic
cell death. For example, leakage of cathepsins to mitochondria can disrupt the mitochondrial membrane and may induce intrinsic apoptotic events [27].
We focused on the underlying mechanism(s) by which HIV, ethanol metabolite(s),
and their combination impaired lysosome activity. To mimic ethanol metabolism in hepatocytes, we exposed CYP2E1-expressing RLW cells to AGS. Lysosome leakage (LL) is
one mechanism that leads to a decline in lysosome hydrolytic potency. The pathogenic
impact of LL in the liver has already been discussed for non-alcoholic [33,34] and alcoholic
steatohepatitis [35]. It was also implicated in the liver injury of ethanol-fed rodents [35,36].
However, this is the first time it has been investigated in non-immune cells (hepatocytes)
after HIV infection and treatment with ethanol metabolites. In our hands, the treatment of
both HIV-infected and -uninfected RLW cells with AGS lowered the expression of LAMP1,
a lysosomal membrane protein important for maintaining lysosome structural integrity.
These findings indicate that acetaldehyde exposure causes lysosomal membrane instability.
The decrease in lysosomal numbers and functions were, at least in part, triggered by ethanol
metabolite-induced oxidative stress since lysosome instability was attenuated by treatment
with the antioxidant NAC. In fact, lysosomes do not express anti-oxidative enzymes, and
they are sensitive to the effects of ROS, which easily destabilize lysosomal membranes [27].
Indeed, ROS have been shown to trigger LL in alcoholic steatohepatitis [34].
In the current study, co-localization of LAMP1 and galectin 3 reported by others as
an indication of increased lysosomal permeability [37] was highest in AGS-treated HIVinfected RLW cells. While the role of HIV-induced lysosomal damage has not been studied
in hepatocytes before, in CD4+ lymphocytes, HIV potentiates LL by activating lysosome-colocalized protein, DRAM1, responsible for lysosome membrane permeabilization (LMP) [24].
Furthermore, DRAM1 regulates apoptosis by increasing the lysosomal localization of proapoptotic protein BAX [38] and has p53 as its downstream target [39]. Therefore, by
measuring p53 gene activation in AGS + HIV-treated RLW cells, we identified a significant
increase in p53 mRNA levels. Because p53-mediated apoptosis is caspase-dependent [40],
to preserve DRAM1-expressing RLW cells, we tested the effects of HIV and AGS treatments
on DRAM1 expression in the presence of pan-caspase inhibitor (PCI) and found increased
levels of DRAM1 in these double-treated cells compared with untreated (control) cells and
cells exposed to either HIV or AGS. These changes were not observed in the absence of
PCI because DRAM1-expressing cells undergo robust caspase-dependent apoptosis. Thus,
it is likely that by activating p53-mediated genes in hepatocytes, DRAM1 contributes to
apoptosis induction, demonstrating the link between LL and apoptotic cell death.
The link between LL and HIV–AGS-induced apoptosis in hepatocytes is still unclear.
When RLW cells were exposed to both HIV and AGS, leading to the highest levels of
apoptotic cell death based on the results of M30 ELISA, we observed the localization of
cathepsin B to mitochondria (specifically, to Tom20 [41]), indicating cathepsin B translocation to mitochondria may be pro-apoptotic. This translocation can trigger caspase
3 cleavage and subsequent apoptotic cell death via upstream activation of caspase 9 by
cytochrome C’s release from permeable mitochondria. In our hands, inhibition of caspase
9 by the specific blocker significantly suppressed HIV–AGS-induced caspase 3 cleavage,
and this effect was more profound than the contribution of caspase 8 inhibition to caspase
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3 cleavage, suggesting that activation of the intrinsic apoptotic pathway plays a major
role in HIV + AGS-induced hepatocyte death. This prompts us to suggest that further
investigations are warranted to study the interdependence of lysosomal and mitochondrial leakages in the pathogenesis of HIV and ethanol-metabolism-induced hepatotoxicity.
However, since this is a highly complex and important area, we did not plan to intensively
investigate lysosome–mitochondrial interactions in the frame of this study, but we intend
to detail this crosstalk in future experiments. While in other studies, the role of LL and
mitochondrial dysfunction for apoptosis induction has already been demonstrated [42–44],
it has never been implemented into the lysosome–mitochondrion axis driving HIV-ethanolmetabolism-induced hepatotoxicity.
There are multiple compensatory mechanisms that remove damaged lysosomes by
autophagy/lysophagy [45–51]. Major repair mechanisms are usually related to lysosome
biogenesis via TFEB [45]. Here, we found that TFEB translocation from cytosol to the
nucleus is necessary to activate lysosome-biogenesis-regulating genes and that this was
impaired in AGS-exposed, HIV-infected hepatic cells. Indeed, the attenuation of TFEB
translocation by ethanol metabolism in hepatocytes was reported before [13,52–54], but
not in the context of HIV liver studies.
To address the mechanisms by which AGS (mainly acetaldehyde) inhibits TFEB
nuclear translocation in hepatocytes in the settings of HIV, we tested the factors which
regulate TFEB stabilization in the cytosol.
A variety of proteins and kinases control the translocation of TFEB to the nucleus to
activate lysosomal biogenesis [15,16,55,56]. In this regard, we explored the role of phosphorylation as a post-translational modification that determines TFEB cytosolic accumulation in
acetaldehyde-treated cells. Thus, phospho-TFEB dimerizes with TFEB to promote the retention of TFEB in the cytosol [57], which we observed in AGS-exposed, HIV-infected hepatocytes.
mTOR phosphorylates TFEB at multiple serine residues (S122, S142, and S211). However,
despite TFEB retention in cytosol, we even found the downregulation of acetaldehyde-induced
TFEB phosphorylation at S211 [15]. The partial explanation for this event might be related
to the overexpression of galectins in acetaldehyde-exposed liver cells due to their enhanced
damage, leading to suppression of mTOR [58]. However, while we have no evidence that
acetaldehyde increases TFEB phosphorylation, some other downstream acetaldehyde-affected
events (e.g., aggregation) might account for TFEB cytosolic retention.
Given that TFEB is a substrate for the proteasome, we measured proteasome activities
in HIV-infected and -uninfected RLW cells exposed or not to AGS and found a concomitant
downregulation of chymotrypsin and trypsin-like proteasome activities. While there is no
evidence of synergistic interactions between HIV and AGS, this is a novel finding because,
to our knowledge, there are no studies that demonstrate the effects of acetaldehyde on
TFEB in relation to proteasome activity in HIV-infected hepatocytes. The most likely
scenario in ethanol-treated hepatic cells is the degradation of non-ubiquitylated TFEB
by 20S proteasome because high oxidative stress causes the dissociation of 19S from
20S proteasome, thereby limiting its ability to recognize non-ubiquitinated substrates
by the 26S proteasome [9]. In HIV-noninfected liver cells, we and others [7,59–62] have
previously reported that ethanol or acetaldehyde impair chymotrypsin-like and trypsin-like
activities of 20S proteasome catalytic core. We cannot exclude that proteasome dysfunction
under HIV–AGS cell exposure attenuates the degradation of total TFEB in the cytosolic
compartment. This undegraded TFEB should translocate to the nucleus for gene activation
if its trafficking is not blocked.
The trafficking of TFEB by microtubules has not been reported before. However,
in hepatocytes, the translocation of some other transcription factors such as STAT3 and
STAT5B from cytosol to the nucleus is suppressed by ethanol metabolism, which impairs
their trafficking due to microtubule acetylation [63,64]. Here, we observed that nocodazole,
an inhibitor of microtubule trafficking, suppressed TFEB translocation to the nucleus in
RLW cells. These findings indicate that microtubules are necessary for TFEB translocation
from cytosol to nucleus. While based on our findings, HIV by itself does not induce
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acetylation of microtubules, in infected and non-infected RLW cells, AGS exposure increases
TFEB acetylation, which negatively affects TFEB trafficking to the nucleus, resulting in its
cytosolic retention.
Overall, the alcohol-impaired lysosomal biogenesis in HIV-infected hepatic cells is
multifactorial, including the reduced translocation of TFEB to the nucleus. The latter may
be attributed to decreased degradation of non-ubiquitylated TFEB by 20S proteasome in
cytosol combined with acetaldehyde-impaired TFEB trafficking to the nucleus. Additionally, exposure of RLW cells to AGS increases the expression of master repressor ZKSCAN3
that blocks TFEB target gene activation, thereby suppressing lysosomal genes. To our
knowledge, this transcriptional repressor of lysosome genes has never been explored in the
context of the combined treatment of hepatocytes with acetaldehyde and HIV.
It became clear from our results and discussion that some downstream events we addressed in this study were a result of synergistic/additive effects of HIV with acetaldehyde.
However, there are a lot of effects that were related to the properties of acetaldehyde without synergizing with HIV; while not synergistic/additive, they are still very important in
mimicking the role of ethanol metabolism in the pathogenesis of HIV-induced liver injury in
alcohol-abusing PLWH. To sort out the events which are “specific” for HIV-infected hepatocytes only and/or are more general in ethanol-metabolite-exposed liver cells was one of the
purposes of this study, and the results are summarized in Table 1. Importantly, the changes
in cathepsin activities, LL-related parameters (DRAM1 expression and LAMP1–Galectin 3
co-localization) as well as caspase 3 cleavage and TFEB translocation to nucleus was higher in
AGS-exposed HIV-infected than in non-infected liver cells and are the results of synergistic or
additive effects from both exposures—HIV and ethanol metabolites.
Table 1. Endpoints of the current study regulated by AGS only or by the combination of AGS/ethanol with HIV.
Parameters

Effect Due To:

Figures

Cathepsin B activity

AGS + HIV

Figure 1A

Cathepsin L activity

AGS + HIV

Figure 1B

LAMP1 immunostaining

AGS

Figure 1C,D

LAMP1 Western blot

AGS + HIV

Figure 1E,F

p53 mRNA

AGS

Figure 2A

DRAM1

AGS + HIV

Figure 2D,E

LAMP1 + Galectin 3 immunostaining

AGS + HIV

Figure 2F,G

Cathepsin B restoration by NAC

AGS + HIV—higher magnitude

Figure 3A

Cathepsin L restoration by NAC

AGS + HIV—higher magnitude

Figure 3B

M30

AGS + HIV

Figure 3C

Tom20 + Cathepsin B immunostaining

AGS + HIV

Figure 4A,B

Cleaved caspase 3

AGS + HIV

Figure 4C,D

Nuclear TFEB/Cyto TFEB

AGS + HIV

Figure 5A,B

PTFEB (S211)

AGS

Figure 5D,E

Acetylated Tubulin

AGS

Figure 5H,I

Chymotrypsin-like activity

AGS

Figure 6A

Trypsin-like activity

AGS

Figure 6B

ZKSCAN3

AGS

Figure 6C,D

LAMP1 mRNA

AGS + HIV

Figure 6E

Cathepsin D

AGS + HIV

Figure 6E
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The proposed mechanism by which HIV and ethanol metabolism induce lysosome
insufficiency contributing to hepatocyte cell death is summarized in Figure 7.

Figure 7. Role of lysosomal rupture/dysfunction in HIV- and ethanol-metabolism-induced apoptosis in hepatocytes:
(1) Combined treatment with HIV and AGS triggers ROS and acetaldehyde release, which mediates lysosome leakage;
(2) HIV/ethanol metabolism triggers the release of DRAM1, which also induces lysosome leakage; (3) Cathepsin B leaked
out from damaged lysosome and diffused into the mitochondrion to initiate the intrinsic apoptotic pathway; (4) Caspases 9
and 3 become cleaved, leading to hepatocyte apoptosis; (5) Alcohol metabolites inhibit lysosome biogenesis factor TFEB,
hence impairing the compensation of damaged lysosomes; and (6) Both lysosome damage and impaired lysosome biogenesis
lead to HIV–ethanol-metabolism-induced lysosome dysfunction, which triggers apoptosis.

5. Conclusions
Findings from this study revealed acetaldehyde- and HIV-induced lysosomal leakage and TFEB dysregulation as the mechanisms of oxidative-stress-induced lysosome
dysfunction in liver cells, which leads to hepatotoxic events. Therapeutic prevention of
HIV–alcohol-triggered hepatotoxicity may be based on the identification and detailed
characterization of these possible targets.
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